Navigation Links
Hyperion Therapeutics Elects Lota Zoth to Board of Directors
Date:4/7/2008

SOUTH SAN FRANCISCO, Calif., April 7, 2008 /PRNewswire/ -- Hyperion Therapeutics, Inc., a privately held biopharmaceutical company, today announced that Lota S. Zoth has been elected to the company's Board of Directors. Ms. Zoth formerly served as Senior Vice President and Chief Financial Officer of MedImmune, Inc. with oversight of finance, information technology and public affairs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070905/AQW076LOGO)

In discussing her appointment, Ms. Zoth commented, "Hyperion's co-promotion agreements and strong product pipeline make it a very attractive opportunity. I look forward to helping the Hyperion team continue to execute on its growth objectives."

Prior to MedImmune, Ms. Zoth was Chief Accounting Officer for PSINet, Inc. and Sodexho Marriott Services, Inc., both of which were publicly-held companies. She also served in various finance executive roles at Marriott International and PepsiCo, Inc. after spending almost a decade at Ernst & Young as an audit executive. Ms. Zoth is a certified public accountant and holds a bachelor's of business administration degree in accounting from Texas Tech University.

"Lota's extensive financial and operational background will be a valuable addition to our Board of Directors," said Chris Rivera, President and Chief Executive Officer of Hyperion Therapeutics, Inc. "We look forward to her contributions as we build out our financing strategies with an eye towards accessing the public markets."

About Hyperion Therapeutics

Hyperion Therapeutics is a fully-integrated specialty therapeutics company committed to becoming a global leader in the development and commercialization of hepatology and gastrointestinal therapies that address orphan or underserved patient populations with unmet medical needs. Hyperion's commercial operations division currently markets two products in the United States for urea cycle disorder. The Company is also conducting two phase II trials, one in the chronic treatment of urea cycle disorder and the other in the treatment of acute hepatic encephalopathy. Hyperion is headquartered in South San Francisco, CA. For additional information, visit http://www.hyperiontx.com.


'/>"/>
SOURCE Hyperion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
2. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
3. Antisense therapeutics scientist out to pull more big deals
4. Vista Partners Initiates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx)
5. Transition Therapeutics to Present at Cowen & Company 28th Annual Healthcare Conference
6. Juvaris BioTherapeutics, Inc. Announces the Appointment of Grant E. Pickering as Chief Executive Officer
7. Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
8. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results
9. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
10. Bayer HealthCare and Juvaris BioTherapeutics Announce Major Licensing Agreement
11. Cell Therapeutics, Inc. Announces Issuance of $51.7 Million of New 2012 Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... CTNext , Connecticut’s ... Awards (EIA), held this past Thursday night at The Space in Hamden. ... their innovative project ideas to a panel of judges for an opportunity to ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... rallying cry to Americans to watch for the discomforts and hidden dangers of ... to senior citizens, everyone is at risk for developing fungal infections on the ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... unveiled the MirixaPro 6.0 platform. As the industry’s leading Medication Therapy Management ... delivered. Based on industry research and market feedback, the latest version of ...
(Date:9/19/2017)... Philadelphia, PA (PRWEB) , ... September 19, 2017 ... ... high-quality orthopedic dog beds, has been officially recognized for its September 2016 donation ... , The company recently received three awards and honors for its contribution ...
(Date:9/19/2017)... ... ... Public outrage over the toxins that exist in tap water and the lack ... itself to research, develop and ultimately supply consumers with healthy drinking water alternatives. Vitev ... alkaline water technologies, water filtration systems, and consumer education. , ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical Supplies, ... supplier of medical equipment, supplies, drugs, vaccines, and specialty ... entered into an agreement to acquire Vantage Medical Supplies, ... in Holtsville, New York . ... supplying new and emerging medical practices, will operate under ...
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), the company commercializing ... Pharma AG to distribute NuvoAir,s spirometry technology to physicians worldwide. ... platform and Novartis, commitment to address the unmet medical needs ... ... "We are ...
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a ... it will host an educational session focused on the ... infection (CLABSI) prevention at the 2017 Annual Scientific Meeting ... will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
Breaking Medicine Technology: